Chordate Medical Holding AB Total Liabilities
Chordate Medical Holding AB total liabilities. Based on the latest financial reports, Chordate Medical Holding AB (CMH) has total liabilities worth Skr4.14 Million SEK (≈ $445.82K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Chordate Medical Holding AB's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chordate Medical Holding AB (2015–2024)
Total liabilities of Chordate Medical Holding AB from 2015 to 2024. This chart illustrates how Chordate Medical Holding AB's total liabilities have evolved over time, based on quarterly financial data.
Chordate Medical Holding AB Competitors by Total Liabilities
The table below lists competitors of Chordate Medical Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Malvern International
LSE:MLVN
|
UK | GBX13.30 Million |
|
STRATA Skin Sciences Inc
NASDAQ:SSKN
|
USA | $27.61 Million |
|
Carisma Therapeutics Inc.
NASDAQ:CARM
|
USA | $7.42 Million |
|
FAT Brands Inc
NASDAQ:FATBW
|
USA | $1.79 Billion |
|
Ukrproduct Group
LSE:UKR
|
UK | GBX14.99 Million |
|
Hamak Gold Ltd
LSE:HAMA
|
UK | GBX1.11 Million |
|
WICKET GAMING AB
F:7Q4
|
Germany | €35.31 Million |
|
Sonder Holdings Inc
NASDAQ:SOND
|
USA | $1.49 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Chordate Medical Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CMH current and non-current assets.
Liquidity & Leverage Metrics
Chordate Medical Holding AB Total Liabilities Ratios Explained
Chordate Medical Holding AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chordate Medical Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chordate Medical Holding AB (2015–2024)
The table below shows the annual total liabilities of Chordate Medical Holding AB from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr8.34 Million ≈ $897.00K |
+21.35% |
| 2023-12-31 | Skr6.87 Million ≈ $739.21K |
-9.24% |
| 2022-12-31 | Skr7.57 Million ≈ $814.43K |
+48.07% |
| 2021-12-31 | Skr5.11 Million ≈ $550.03K |
-8.33% |
| 2020-12-31 | Skr5.58 Million ≈ $600.04K |
-29.17% |
| 2019-12-31 | Skr7.87 Million ≈ $847.21K |
-20.14% |
| 2018-12-31 | Skr9.86 Million ≈ $1.06 Million |
-9.68% |
| 2017-12-31 | Skr10.91 Million ≈ $1.17 Million |
-5.73% |
| 2016-12-31 | Skr11.58 Million ≈ $1.25 Million |
-2.60% |
| 2015-12-31 | Skr11.89 Million ≈ $1.28 Million |
-- |
About Chordate Medical Holding AB
Chordate Medical Holding AB (publ), a medical technology company, engages in the development of products and solutions for neurostimulation treatment in Sweden. It offers Ozilia, a neuromodulation and medication-free treatment technology for chronic migraine and chronic rhinitis. The company was founded in 2005 and is based in Kista, Sweden.